Dr. Elias Sayour

elias-sayourAssistant Professor of Neurosurgery and Pediatrics
Pediatric Hematology/Oncology
UF Health Shands Children’s Hospital

Office: (352) 273-9120
Fax: (352) 294-8091
Address: UF Pediatrics, Division of Hematology/Oncology
Box 100298
Gainesville, FL 32610-0298
Email: elias.sayour@neurosurgery.ufl.edu


  • Bachelor of Science: Fordham University, 1999-2003
  • Doctor of Medicine: University at Buffalo, School of Medicine and Biomedical Sciences, 2003-2007
  • Residency: Cohen Children’s Medical Center of New York, 2007-2010
  • Fellowship: Duke University Medical Center, 2010-2013
  • Doctor of Philosophy: Duke University, 2012-2015

Board Certification

  • Pediatrics, 2010-present
  • Pediatric Hematology-Oncology, 2015-present

Clinical Interests

  • Immunotherapy
  • Nanotechnology
  • Adoptive Cellular Therapy
  • Neuro-Oncology


Elias Sayour, M.D., Ph.D. is an Assistant Professor of Neurosurgery and Pediatrics and Principal Investigator of the RNA Engineering Laboratory within the Preston A. Wells, Jr. Center for Brain Tumor Therapy and UF Brain Tumor Immunotherapy Program.   Dr. Sayour trained at Duke University where he completed a pediatric hematology-oncology fellowship and NIH research fellowship in cancer biology and developmental therapeutics. He also enrolled in the Duke University Graduate School and completed his Ph.D. in 2015.

Dr. Sayour’s main focus is deeply rooted in harnessing the immune system to eradicate pediatric cancers. He has received several extramural grants to support his research efforts including the Hyundai Hope on Wheels Hope Award, ASPHO Young Investigator Award, and the American Brain Tumor Association Discovery Award. Dr. Sayour has been involved in translating bench work into clinical trials governing the development of dendritic cell vaccines with adoptively transferred cytotoxic T cells against recurrent medulloblastoma. He has also started an integrative pediatric immunotherapy working group at UF that includes surgeons, clinicians, veterinarians, and pre-clinical scientists working to advance novel directed therapeutics against refractory malignancies.   Their goals are to identify novel antigen targets and construct robust immunotherapeutic treatments against these malignancies.